VNDA
Vanda Pharmaceuticals Inc.
Price Chart
Latest Quote
$5.73
-0.15 (-2.55%)
Current Price
| Previous Close | $5.88 |
| Open | $5.88 |
| Day High | $5.93 |
| Day Low | $5.61 |
| Volume | 936,343 |
Stock Information
| Shares Outstanding | 60.14M |
| Total Debt | $13.07M |
| Cash Equivalents | $202.31M |
| Revenue | $217.78M |
| Net Income | $-239.55M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $344.58M |
| EPS (TTM) | $-4.06 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $155.34M |
| Sales | $217.78M |
| Income | $-239.55M |
| Book/sh | $5.54 |
| Cash/sh | $3.36 |
| Employees | 533 |
Financial Ratios
| Quick Ratio | 1.91 |
| Current Ratio | 2.16 |
| Debt/Eq | 4.66 |
Returns & Margins
| ROA | -18.81% |
| ROE | -60.48% |
| Gross Margin | 94.18% |
| Operating Margin | -97.11% |
| Profit Margin | -109.99% |
Ownership
| Insider Ownership | 6.65% |
| Institutional Ownership | 78.25% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 28.65 |
| PEG | 2.23 |
| P/S | 1.58 |
| P/B | 1.04 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $14.12 |
Technical Indicators
| SMA20 | $6.14 |
| SMA50 | $6.60 |
| SMA200 | $6.38 |
| RSI | 31.09 |
| ATR | 0.2650 |
| Shares Float | 53.84M |
| Short Float | 11.89% |
| Short Ratio | 5.87 |
| Volatility | 0.60 |
| Rel Volume | 1.02 |
Performance History
| Week | -6.37% |
| Month | -8.76% |
| Quarter | -33.37% |
| 6 Months | -8.03% |
| YTD | -30.55% |
| Year | +27.05% |
| 3 Years | -11.85% |
| 5 Years | -69.42% |
| 10 Years | -47.24% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-16 | $5.73 | 944,600 |
| 2026-06-15 | $5.88 | 1,131,000 |
| 2026-06-12 | $5.87 | 1,320,000 |
| 2026-06-11 | $6.10 | 991,900 |
| 2026-06-10 | $6.03 | 855,900 |
| 2026-06-09 | $6.12 | 825,700 |
| 2026-06-08 | $5.94 | 786,600 |
| 2026-06-05 | $6.03 | 714,400 |
| 2026-06-04 | $6.25 | 671,500 |
| 2026-06-03 | $6.09 | 813,000 |
| 2026-06-02 | $6.13 | 927,400 |
| 2026-06-01 | $6.37 | 940,700 |
| 2026-05-29 | $6.45 | 809,000 |
| 2026-05-28 | $6.64 | 1,186,000 |
| 2026-05-27 | $6.46 | 1,181,000 |
| 2026-05-26 | $6.22 | 884,500 |
| 2026-05-22 | $6.19 | 884,100 |
| 2026-05-21 | $6.21 | 748,700 |
| 2026-05-20 | $6.18 | 1,179,900 |
| 2026-05-19 | $5.99 | 804,000 |
| 2026-05-18 | $6.08 | 1,419,200 |
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
đ° Latest News
How The Vanda Pharmaceuticals (VNDA) Investment Story Is Shifting With BYSANTI And Nereus
Simply Wall St. âĸ 2026-05-18T03:14:36Z
Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?
Insider Monkey âĸ 2026-05-10T23:13:55Z
Vanda Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T08:18:19Z
Vanda Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-07T00:26:46Z
Vanda (VNDA) Q1 2026 Earnings Call Transcript
Motley Fool âĸ 2026-05-06T22:28:20Z
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-06T21:10:02Z
Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should Know
Zacks âĸ 2026-05-05T13:55:03Z
Sector Update: Health Care Stocks Softer in Afternoon Trading
MT Newswires âĸ 2026-05-04T17:58:59ZIncyte (INCY) Beats Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-04-28T12:15:04Z
Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal Officer
Insider Monkey âĸ 2026-04-25T21:06:26Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $8,134,000 | $8,788,000 | $12,552,000 | $23,065,000 |
| Cost Of Revenue | $13,044,000 | $11,314,000 | $14,796,000 | $24,282,000 |
| Total Revenue | $216,105,000 | $198,772,000 | $192,640,000 | $254,382,000 |
| Operating Revenue | $216,105,000 | $198,772,000 | $192,640,000 | $254,382,000 |
| Expenses | ||||
| Total Expenses | $367,273,000 | $239,432,000 | $206,592,000 | $248,053,000 |
| Other Income Expense | $12,521,000 | $17,739,000 | $20,291,000 | $4,971,000 |
| Other Non Operating Income Expenses | $12,521,000 | $17,739,000 | $20,291,000 | $4,971,000 |
| Operating Expense | $354,229,000 | $228,118,000 | $191,796,000 | $223,771,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-220,474,000 | $-18,900,000 | $2,509,000 | $6,275,000 |
| Normalized Income | $-220,474,000 | $-18,900,000 | $2,509,000 | $6,275,000 |
| Net Income From Continuing And Discontinued Operation | $-220,474,000 | $-18,900,000 | $2,509,000 | $6,275,000 |
| Total Operating Income As Reported | $-151,168,000 | $-40,660,000 | $-13,952,000 | $6,329,000 |
| Net Income Common Stockholders | $-220,474,000 | $-18,900,000 | $2,509,000 | $6,275,000 |
| Net Income | $-220,474,000 | $-18,900,000 | $2,509,000 | $6,275,000 |
| Net Income Including Noncontrolling Interests | $-220,474,000 | $-18,900,000 | $2,509,000 | $6,275,000 |
| Net Income Continuous Operations | $-220,474,000 | $-18,900,000 | $2,509,000 | $6,275,000 |
| Pretax Income | $-138,647,000 | $-22,921,000 | $6,339,000 | $11,300,000 |
| Operating Income | $-151,168,000 | $-40,660,000 | $-13,952,000 | $6,329,000 |
| Depreciation Amortization Depletion Income Statement | $7,007,000 | $7,273,000 | $2,090,000 | $1,516,000 |
| Depreciation And Amortization In Income Statement | $7,007,000 | $7,273,000 | $2,090,000 | $1,516,000 |
| Amortization Of Intangibles Income Statement | $7,007,000 | $7,273,000 | $2,090,000 | $1,516,000 |
| Gross Profit | $203,061,000 | $187,458,000 | $177,844,000 | $230,100,000 |
| Per Share | ||||
| Diluted EPS | $-3.74 | $-0.33 | $0.04 | $0.11 |
| Basic EPS | $-3.74 | $-0.33 | $0.04 | $0.11 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-139,251,000 | $-30,861,000 | $-9,618,000 | $9,062,000 |
| Reconciled Depreciation | $11,917,000 | $9,799,000 | $4,334,000 | $2,733,000 |
| EBITDA (Bullshit earnings) | $-139,251,000 | $-30,861,000 | $-9,618,000 | $9,062,000 |
| EBIT | $-151,168,000 | $-40,660,000 | $-13,952,000 | $6,329,000 |
| Diluted Average Shares | $58,930,157 | $58,149,087 | $57,557,911 | $56,983,171 |
| Basic Average Shares | $58,930,157 | $58,149,087 | $57,380,975 | $56,461,877 |
| Diluted NI Availto Com Stockholders | $-220,474,000 | $-18,900,000 | $2,509,000 | $6,275,000 |
| Tax Provision | $81,827,000 | $-4,021,000 | $3,830,000 | $5,025,000 |
| Amortization | $7,007,000 | $7,273,000 | $2,090,000 | $1,516,000 |
| Research And Development | $109,271,000 | $74,431,000 | $76,823,000 | $85,770,000 |
| Selling General And Administration | $237,951,000 | $146,414,000 | $112,883,000 | $136,485,000 |
Fetched: 2026-06-12
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $210,097,000 | $424,450,000 | $423,541,000 | $508,633,000 |
| Total Assets | $488,948,000 | $656,204,000 | $648,440,000 | $634,247,000 |
| Total Non Current Assets | $141,686,000 | $217,314,000 | $215,494,000 | $114,955,000 |
| Other Non Current Assets | $11,083,000 | $9,101,000 | $9,985,000 | $11,378,000 |
| Non Current Deferred Assets | $0 | $81,440,000 | $75,000,000 | $74,039,000 |
| Non Current Deferred Taxes Assets | $0 | $81,440,000 | $75,000,000 | $74,039,000 |
| Goodwill And Other Intangible Assets | $117,089,000 | $114,096,000 | $121,369,000 | $18,565,000 |
| Other Intangible Assets | $117,089,000 | $114,096,000 | $121,369,000 | $18,565,000 |
| Current Assets | $347,262,000 | $438,890,000 | $432,946,000 | $519,292,000 |
| Other Current Assets | $26,985,000 | $15,420,000 | $9,170,000 | $17,727,000 |
| Inventory | $1,852,000 | $1,726,000 | $1,357,000 | $1,194,000 |
| Receivables | $54,578,000 | $47,101,000 | $34,155,000 | $33,512,000 |
| Accounts Receivable | $54,578,000 | $47,101,000 | $34,155,000 | $33,512,000 |
| Cash Cash Equivalents And Short Term Investments | $263,847,000 | $374,643,000 | $388,264,000 | $466,859,000 |
| Cash And Cash Equivalents | $84,851,000 | $102,316,000 | $135,821,000 | $135,029,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $12,622,000 | $12,360,000 | $9,404,000 | $11,141,000 |
| Long Term Debt And Capital Lease Obligation | $7,067,000 | $8,090,000 | $7,006,000 | $8,813,000 |
| Current Debt And Capital Lease Obligation | $5,555,000 | $4,270,000 | $2,398,000 | $2,328,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $161,762,000 | $117,658,000 | $103,530,000 | $107,049,000 |
| Total Non Current Liabilities Net Minority Interest | $16,600,000 | $17,677,000 | $15,833,000 | $15,613,000 |
| Other Non Current Liabilities | $9,533,000 | $9,587,000 | $8,827,000 | $6,800,000 |
| Current Liabilities | $145,162,000 | $99,981,000 | $87,697,000 | $91,436,000 |
| Payables And Accrued Expenses | $52,420,000 | $26,351,000 | $29,649,000 | $36,384,000 |
| Payables | $42,420,000 | $26,351,000 | $29,649,000 | $36,384,000 |
| Other Payable | $37,480,000 | $22,853,000 | $22,504,000 | $23,694,000 |
| Accounts Payable | $4,940,000 | $3,498,000 | $7,145,000 | $12,690,000 |
| Equity | ||||
| Common Stock Equity | $327,186,000 | $538,546,000 | $544,910,000 | $527,198,000 |
| Total Equity Gross Minority Interest | $327,186,000 | $538,546,000 | $544,910,000 | $527,198,000 |
| Stockholders Equity | $327,186,000 | $538,546,000 | $544,910,000 | $527,198,000 |
| Gains Losses Not Affecting Retained Earnings | $629,000 | $74,000 | $-30,000 | $-1,193,000 |
| Other Equity Adjustments | $629,000 | $74,000 | $-30,000 | $-1,193,000 |
| Retained Earnings | $-394,766,000 | $-174,292,000 | $-155,392,000 | $-157,901,000 |
| Other | ||||
| Ordinary Shares Number | $59,101,630 | $58,310,644 | $57,534,499 | $56,783,764 |
| Share Issued | $59,101,630 | $58,310,644 | $57,534,499 | $56,783,764 |
| Tangible Book Value | $210,097,000 | $424,450,000 | $423,541,000 | $508,633,000 |
| Invested Capital | $327,186,000 | $538,546,000 | $544,910,000 | $527,198,000 |
| Working Capital | $202,100,000 | $338,909,000 | $345,249,000 | $427,856,000 |
| Capital Lease Obligations | $12,622,000 | $12,360,000 | $9,404,000 | $11,141,000 |
| Total Capitalization | $327,186,000 | $538,546,000 | $544,910,000 | $527,198,000 |
| Additional Paid In Capital | $721,264,000 | $712,706,000 | $700,274,000 | $686,235,000 |
| Capital Stock | $59,000 | $58,000 | $58,000 | $57,000 |
| Common Stock | $59,000 | $58,000 | $58,000 | $57,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $7,067,000 | $8,090,000 | $7,006,000 | $8,813,000 |
| Current Capital Lease Obligation | $5,555,000 | $4,270,000 | $2,398,000 | $2,328,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $10,322,000 | $8,465,000 | $6,413,000 | $6,839,000 |
| Current Provisions | $76,865,000 | $60,895,000 | $49,237,000 | $45,885,000 |
| Current Accrued Expenses | $10,000,000 | $0 | - | $18,715,000 |
| Net PPE | $13,514,000 | $12,677,000 | $9,140,000 | $10,973,000 |
| Accumulated Depreciation | $-12,616,000 | $-11,567,000 | $-11,181,000 | $-10,419,000 |
| Gross PPE | $26,130,000 | $24,244,000 | $20,321,000 | $21,392,000 |
| Leases | $5,498,000 | $5,468,000 | $5,438,000 | $5,417,000 |
| Other Properties | $11,266,000 | $10,545,000 | $7,103,000 | $8,400,000 |
| Machinery Furniture Equipment | $9,366,000 | $8,231,000 | $7,780,000 | $7,575,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,852,000 | $1,726,000 | $1,330,000 | $1,171,000 |
| Other Short Term Investments | $178,996,000 | $272,327,000 | $252,443,000 | $331,830,000 |
| Work In Process | - | $0 | $27,000 | $23,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-12
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-110,440,000 | $-16,247,000 | $12,418,000 | $31,305,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-109,442,000 | $-15,757,000 | $12,801,000 | $31,984,000 |
| Cash Flow From Continuing Operating Activities | $-109,442,000 | $-15,757,000 | $12,801,000 | $31,984,000 |
| Operating Gains Losses | - | - | $655,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-998,000 | $-490,000 | $-383,000 | $-679,000 |
| Investing Cash Flow | $94,860,000 | $-17,430,000 | $-12,056,000 | $49,925,000 |
| Cash Flow From Continuing Investing Activities | $94,860,000 | $-17,430,000 | $-12,056,000 | $49,925,000 |
| Net Other Investing Changes | - | $-4,229,000 | $-100,665,000 | - |
| Financing Activities | ||||
| Financing Cash Flow | $-2,906,000 | $-155,000 | $0 | $734,000 |
| Cash Flow From Continuing Financing Activities | $-2,906,000 | $-155,000 | $0 | $734,000 |
| Net Other Financing Charges | $-915,000 | - | - | - |
| Other | ||||
| Repayment Of Debt | $-1,991,000 | $-155,000 | $0 | $0 |
| End Cash Position | $85,320,000 | $102,785,000 | $136,290,000 | $135,498,000 |
| Beginning Cash Position | $102,785,000 | $136,290,000 | $135,498,000 | $52,590,000 |
| Effect Of Exchange Rate Changes | $23,000 | $-163,000 | $47,000 | $265,000 |
| Changes In Cash | $-17,488,000 | $-33,342,000 | $745,000 | $82,643,000 |
| Net Issuance Payments Of Debt | $-1,991,000 | $-155,000 | $0 | $0 |
| Net Long Term Debt Issuance | $-1,991,000 | $-155,000 | $0 | $0 |
| Long Term Debt Payments | $-1,991,000 | $-155,000 | $0 | $0 |
| Net Investment Purchase And Sale | $95,858,000 | $-12,711,000 | $88,992,000 | $50,604,000 |
| Sale Of Investment | $208,237,000 | $352,062,000 | $601,598,000 | $399,862,000 |
| Purchase Of Investment | $-112,379,000 | $-364,773,000 | $-512,606,000 | $-349,258,000 |
| Net PPE Purchase And Sale | $-998,000 | $-490,000 | $-383,000 | $-679,000 |
| Purchase Of PPE | $-998,000 | $-490,000 | $-383,000 | $-679,000 |
| Change In Working Capital | $8,308,000 | $-6,558,000 | $-747,000 | $6,074,000 |
| Change In Other Working Capital | $15,484,000 | $11,591,000 | $3,192,000 | $5,985,000 |
| Change In Payables And Accrued Expense | $15,820,000 | $1,708,000 | $-10,984,000 | $11,793,000 |
| Change In Payable | $15,820,000 | $1,708,000 | $-10,984,000 | $11,793,000 |
| Change In Account Payable | $15,820,000 | $1,708,000 | $-10,984,000 | $11,793,000 |
| Change In Prepaid Assets | $-12,067,000 | $-6,816,000 | $8,523,000 | $-6,136,000 |
| Change In Inventory | $-3,466,000 | $-29,000 | $-771,000 | $-4,479,000 |
| Change In Receivables | $-7,463,000 | $-13,012,000 | $-707,000 | $-1,089,000 |
| Changes In Account Receivables | $-7,463,000 | $-13,012,000 | $-707,000 | $-1,089,000 |
| Other Non Cash Items | $1,943,000 | $946,000 | $2,095,000 | $2,456,000 |
| Stock Based Compensation | $9,474,000 | $12,432,000 | $14,040,000 | $16,279,000 |
| Amortization Of Securities | $-2,053,000 | $-6,994,000 | $-8,799,000 | $-2,963,000 |
| Deferred Tax | $81,443,000 | $-6,482,000 | $-1,286,000 | $1,130,000 |
| Deferred Income Tax | $81,443,000 | $-6,482,000 | $-1,286,000 | $1,130,000 |
| Depreciation Amortization Depletion | $11,917,000 | $9,799,000 | $4,334,000 | $2,733,000 |
| Depreciation And Amortization | $11,917,000 | $9,799,000 | $4,334,000 | $2,733,000 |
| Amortization Cash Flow | $7,007,000 | $7,273,000 | $2,090,000 | $1,516,000 |
| Amortization Of Intangibles | $7,007,000 | $7,273,000 | $2,090,000 | $1,516,000 |
| Depreciation | $4,910,000 | $2,526,000 | $2,244,000 | $1,217,000 |
| Net Income From Continuing Operations | $-220,474,000 | $-18,900,000 | $2,509,000 | $6,275,000 |
| Proceeds From Stock Option Exercised | - | $0 | $0 | $734,000 |
| Net Business Purchase And Sale | - | - | $-100,665,000 | $0 |
| Purchase Of Business | - | - | $-100,665,000 | $0 |
| Gain Loss On Investment Securities | - | - | $655,000 | - |
Fetched: 2026-06-12